322 related articles for article (PubMed ID: 30738089)
1. Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.
Hong JY; Chen TH; Chen YJ; Liu CC; Jan JT; Wu SC
Antiviral Res; 2019 Apr; 164():12-22. PubMed ID: 30738089
[TBL] [Abstract][Full Text] [Related]
2. Production of Multi-Subtype Influenza Virus-Like Particles by Molecular Fusion with BAFF or APRIL for Vaccine Development.
Chen TH; Hong JY; Liu CC; Chen CC; Jan JT; Wu SC
Methods Mol Biol; 2021; 2248():139-153. PubMed ID: 33185873
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
[TBL] [Abstract][Full Text] [Related]
4. Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.
Kang HJ; Chu KB; Yoon KW; Eom GD; Mao J; Kim MJ; Lee SH; Moon EK; Quan FS
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216022
[TBL] [Abstract][Full Text] [Related]
5. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
[TBL] [Abstract][Full Text] [Related]
6. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
Crevar CJ; Carter DM; Lee KY; Ross TM
Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
8. Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.
Pushko P; Sun X; Tretyakova I; Hidajat R; Pulit-Penaloza JA; Belser JA; Maines TR; Tumpey TM
Vaccine; 2016 Oct; 34(44):5235-5242. PubMed ID: 27663671
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
Smith GE; Sun X; Bai Y; Liu YV; Massare MJ; Pearce MB; Belser JA; Maines TR; Creager HM; Glenn GM; Flyer D; Pushko P; Levine MZ; Tumpey TM
Virology; 2017 Sep; 509():90-97. PubMed ID: 28624679
[TBL] [Abstract][Full Text] [Related]
10. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
Khurana S; Wu J; Verma N; Verma S; Raghunandan R; Manischewitz J; King LR; Kpamegan E; Pincus S; Smith G; Glenn G; Golding H
J Virol; 2011 Nov; 85(21):10945-54. PubMed ID: 21865396
[TBL] [Abstract][Full Text] [Related]
11. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.
Wei HJ; Chang W; Lin SC; Liu WC; Chang DK; Chong P; Wu SC
Vaccine; 2011 Sep; 29(41):7163-72. PubMed ID: 21651946
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice.
Ren Z; Zhao Y; Liu J; Ji X; Meng L; Wang T; Sun W; Zhang K; Sang X; Yu Z; Li Y; Feng N; Wang H; Yang S; Yang Z; Wang Z; Gao Y; Xia X
Vaccine; 2018 Sep; 36(40):5990-5998. PubMed ID: 30172635
[TBL] [Abstract][Full Text] [Related]
14. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
15. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
16. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.
Giles BM; Bissel SJ; Dealmeida DR; Wiley CA; Ross TM
Clin Vaccine Immunol; 2012 Feb; 19(2):128-39. PubMed ID: 22190399
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
[TBL] [Abstract][Full Text] [Related]
19. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
[TBL] [Abstract][Full Text] [Related]
20. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
